Maltose
CAS 69-79-4
Maltose (CAS 69-79-4) is a Phase 3 pharmaceutical compound with 1 bioactivity target and 662 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | IC50 | 19976.309999999998 nM | 1 | - |
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Appendicolith | 50 | 250.577 | 10074458 |
| Blood phosphorus increased | 47 | 220.936 | 10050196 |
| Appendicitis | 50 | 200.541 | 10003011 |
| Ventricular fibrillation | 51 | 185.84 | 10047290 |
| Cardiogenic shock | 51 | 173.501 | 10007625 |
| Ascites | 51 | 138.036 | 10003445 |
| Stress | 52 | 138.017 | 10042209 |
| Multiple organ dysfunction syndrome | 52 | 121.781 | 10077361 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| MALTOSE | 1311261 | SU | MTHSPL |
| maltose | 1311261 | IN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Maltose used for in pharmaceutical contexts?
Maltose (CAS 69-79-4) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Maltose?
Maltose has 662 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Appendicolith, Blood phosphorus increased, Appendicitis, Ventricular fibrillation, Cardiogenic shock. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Maltose also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Maltose with EU status "permitted".
What clinical phase is Maltose in?
Maltose is rendered with ChEMBL max phase 3.